Shows
Building BiotechsBiotech, Blockchain, and Building Companies with Russ Peloquin, Managing Partner of LifeSci Catalyst PartnersThis week I had a great conversation with Russ Peloquin, Managing Partner of LifeSci Catalyst Partners. We dive into Russ's unique journey from aspiring exterminator (yes, you read that right!) to leading life science entrepreneur, discussing his extensive experience in commercialization, mergers, and acquisitions. Russ shares invaluable insights on the importance of marketing, fundraising strategies for biotech startups, the phases of taking a company from idea to commercialization, and the critical steps toward securing regulatory approvals. We also touch on the intersection of genome sequencing, blockchain, and AI, exploring how this convergence is set to democratize and capitalize on...2024-12-0934 min
CivicSciTV-RadioOn QOTD: VP Monica Malowney from the NYC-Economic Development Corporation discusses their LifeSci NYC initiative to build a diverse talent pipelineThe conversation focuses on Monica Malowney’s work with the New York City Economic Development Corporation (NYC EDC) and their LifeSci NYC initiative. The goal of LifeSci NYC is to make New York City a global leader in the life sciences and strengthen the talent pipeline, with a focus on diversity. https://edc.nyc/program/lifesci-nyc
Key points from Malowney:
She manages the talent strategy for LifeSci NYC. They want to build a robust and diverse talent pipeline for the life sciences industry in NYC.
Black and Hispanic New Yorkers are underrepresented in the scientific workforce. Her work focuses on...2024-04-2030 min
LifeSci Partners PodcastLeveraging AI and ML in Drug R&D: Current and Future Impacts to the Life Sciences IndustryTune into Episode #2 of the LifeSci Search podcast with Andy Cronin (President & Co-Founder) and Ayesha Price (Sr. Director, Executive Search) as they host Iris Grossman (Chief Therapeutics Officer, Eleven Therapeutics) and Shahram Ebadollahi (Operating Partner, ARCHIMED & Former Chief Data Officer, Novartis) on the topic of AI and ML tools in Drug R&D. We get insights on how the tech is being leveraged in biotech and pharma along the R&D process, overall impact so far, thinking around AI and ML among leadership teams & boards, and perspectives on the competition for AI and ML talent within Life Sciences industry.2023-10-0341 min
Signals by AlphaSenseWhat pharma companies need to know about the Inflation Reduction Act (IRA), with Emily Coriale, PharmD, LifeSci ConsultingEpisode SummaryIn this episode, host Nick Mazing from AlphaSense interviews Emily Coriale, Senior Principal Pricing & Market Access Lead at LifeSci Consulting. They discuss the far-reaching implications of the Inflation Reduction Act (IRA) on the US healthcare system, with a particular focus on drug pricing and price negotiations between the US federal government and pharmaceutical companies, as well as the impact on health plans.Emily explains that the IRA is the most significant federal legislation in the last 20 years and highlights three main aspects of the act: drug price negotiation...2023-05-1611 min
LifeSci Partners PodcastLifeSci Search Podcast: Episode #1Tune into Episode #1 of the LifeSci Search Podcast.2023-03-1737 min
LifeSci Partners PodcastA Brief Chat with Amir London, CEO of Kamada Ltd.In this 13-minute chat, Amir London, CEO of Kamada Ltd. (NASDAQ: KMDA), discusses the growing commercial business of the company, including six FDA-approved products for rare and serious conditions, and its innovative development pipeline, targeting areas of significant unmet medical need.2022-12-2813 minLifeSci Partners PodcastA Brief Chat with Rob Etherington, President & CEO of Clene, Inc.In this 15-minute chat, Rob Etherington, President & CEO of Clene, Inc. (NASDAQ: CLNN) discusses the potential for nanosuspensions to improve cellular energy production and treat neurodegenerative diseases, along with Clene’s future directions.2022-12-2714 minLifeSci Partners PodcastHelping the Body Help Itself with EscharEx: The Next Generation Wound-Care Therapeutic from MediWoundRepairing damage to living tissue often requires the removal or debridement of what was destroyed. This is usually done through surgery—an invasive process performed in a clinical setting that is inherently stressful for the patient. EscharEx is none of that. A topically administered biologic, EscharEx is administered in the outpatient setting, and has been shown to be safe, tolerable, and effective. Listen in as MediWound’s incoming CMO Dr. Robert Snyder describes this innovation.2022-12-1626 minLifeSci Partners PodcastA Promising New Immune Checkpoint from Sensei Bio: VISTACTLA-4 was a breakthrough; PD-1—a blockbuster, then IDO got busted and biotech retreated to the bench. It got quiet for a while, but the basic science bounced back, and now we have LAG-3, and on the horizon, a new VISTA. Myeloid cells have the target, and Sensei Bio has the drug. Tune in as CEO John Celebi tells us the story of SNS-101 and why the Fc component is so important.2022-12-1333 minLifeSci Partners PodcastTurning Amino Acids into Drugs: A Novel Platform from Axcella HealthEndogenous metabolic modulators (EMMs) are composed of amino acids and, when given in combination, have the potential to treat serious disease. With their lead EMM compound AXA1125, a proprietary blend of amino acids, Axcella is posed to address the urgent and growing unmet needs in the settings of long COVID and nonalcoholic steatohepatitis (NASH). For long COVID, Axcella aims to generate ATP for patients sapped of energy, and for NASH, it aims to impact metabolic pathways involved in fat storage. Tune in as CEO Bill Hinshaw explains the mechanisms, promise, and related IP.2022-12-0843 minLifeSci Partners PodcastLipocine Inc’s Formulation for Success: Oral Agents for CNS DisordersDrug discovery is an adventure, drug delivery is an art. The chemists at Lipocine put their experience to the test — by turning drugs with problematic administration into oral agents with improved bioavailability. With validation from their recently approved testosterone replacement drug, Tlando®, and the licensing potential of three other oral assets for NASH and pre-term birth, Lipocine is now focused on developing oral formulations for depression and epilepsy. Tune in as CEO Mahesh Patel, PhD, describes his development plans.2022-11-1727 minLifeSci Partners Podcast89bio Aims to Tame NASH and Severe Hypertriglyceridemia (SHTG) with Lead Asset PegozaferminAs the American obesity issue grows, the NASH and SHTG treatment markets concurrently expand. At 89bio, the idea is to use nature itself to therapeutically treat this growing problem. Using their lead asset pegozafermin, an analog of the endogenous hormone fibroblast growth factor 21 (FGF21), to restore metabolic homeostasis and thereby reduce liver fat, as well as triglyceride levels, 89bio is currently advancing their development program in both diseases. Tune in as CEO Rohan Palekar gives updates from the ENLIVEN study for NASH and ENTRIGUE study for SHTG, along with future directions in clinical development.2022-11-1134 minLifeSci Partners PodcastDe-Risked Oncology Targets with Assets from Checkpoint TherapeuticsJames Oliviero, CEO of Checkpoint Therapeutics, is certain that fortunes can be won by building better and cheaper mousetraps. That’s why he is positioned to capture significant market share with assets for the de-risked oncology targets of PD-L1, with Cosibelimab, and EGFR with Olafertinib. For Cosibelimab, an anti-PD-L1 antibody, Checkpoint offers an improved mechanism of action and a lower price point. For Olafertinib, a 3rd generation EGFR inhibitor, the play is a better tolerability profile that will boost patient compliance. Building better traps—that’s the bottom line.2022-11-0435 minLifeSci Partners PodcastDeep Transcranial Magnetic Stimulation (Deep TMS™): BrainsWay’s Innovative and Non-Invasive Therapy for Major Depressive Disorder, Anxious Depression, OCD, and Smoking AddictionThe CEO of BrainsWay Ltd, Christopher von Jako, is committed to non-invasive medical technologies – particularly when it comes to the brain. A businessman with over 30 years of experience in medical devices and a PhD in neurology, Dr. von Jako now spearheads the continued development, sales, and marketing of BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS™) device, a non-invasive, highly effective, and broadly reimbursed therapy for major depressive disorder, anxious depression, OCD, and smoking addiction. Tune into Episode 58 of the Benchtop Bios Podcast Series, where Dr. von Jako highlights the device, supporting data, and company’s plans for an internat...2022-10-2042 minLifeSci Partners PodcastAn Oncology Update on CDK 2/9 Inhibition: Cyclacel PharmaceuticalsIt’s the circle of life: the cell cycle is a molecular merry-go-round for the propagation of all cells, including tumor cells. This process is regulated by cyclin-dependent kinases (CDKs), thus, CDK inhibition has long been a goal of drug developers. However, until very recently, toxicity has remained an issue. Early clinical results suggest that Cyclacel Pharmaceuticals has potentially overcome this hurdle. Tune in as Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, describes Cyclacel’s Phase 1/2 studies with its two clinical stage molecules, including lead asset fadraciclib, a CDK2/9 inhibitor, in patients with solid tumor cancers and hematological malignancies.2022-09-2935 minLifeSci Partners PodcastOncology on the Move—Artios: Financing Considerations for an Early BiotechArtios has raised eyebrows, and cash, raising $320 million since its founding in 2016. Led by CEO, Niall Martin, who spearheaded the development of the PARP inhibitor, Lynparza™, along with the scientific guidance of DDR pioneer, Dr. Graeme Smith, Artios has been able to make a scientific impact. However, in this episode, we will explore their financial impact, as CFO Abid Ansari details how Artios has been able survive and thrive in this challenging market environment.2022-09-1926 minLifeSci Partners PodcastFire Up the Immune System to Lead the Charge Against Cancer: Alligator BioscienceMost oncology drugs turn things off—Alligator Bioscience prefers to turn things on, specifically, the immune system, by way of stimulation with CD40 and 4-1BB agonists. In this podcast, Alligator CEO, Søren Bregenholt, discusses the latest clinical data for lead anti-CD40 asset, mitazalimab, as well as two distinct 4-1BB agonists in development. Additionally, he answers the critical question: How did you tame the toxicity of these signaling molecules when so many others have failed?2022-09-1626 minLifeSci Partners PodcastEsperion Therapeutics: A Small Company with a Big HeartLowering your LDL levels—so-called “bad cholesterol”—can save your life: an irrefutable observation made possible by the advent of statins. The good news is that we have statins by the bucket-full; however, the bad news is that not everyone can tolerate statins (>20%) or they can’t hit LDL-lowering targets with a statin alone. Enter Nexletol (bempedoic acid) and Nexlizet (bempedoic acid plus ezetimibe) for use alone or in combination with a statin. What’s the global market opportunity for these newly approved agents? (Hint: it’s huge). Esperion’s CEO, Sheldon Koenig tells you exactly how Esperion's discoveries will improve on...2022-08-3134 minLifeSci Partners PodcastPatient-centric, Physician-managed healthcare centers that Payers love: P3 Health PartnersMy mother, a woman who thrived on organization, always had her entire medical history in hand when she saw a new healthcare provider—both in hard copy and on disk. No one ever looked at it. Not once. They were not the records of that particular provider and therefore, did not count. And having past test results transferred to a new provider? Good luck with that. Easier to repeat the tests. Not so with patients in the P3 Health Partner systems. Listen in as P3 CEO, Dr. Sherif Abdou, describes his passion, and his plans for refocusing the needs of...2022-08-2230 minLifeSci Partners PodcastTwo Oncology Assets in the Clinic and a sought-after Discovery Platform: Ryvu TherapeuticsRyvu’s lead asset, discovered-inhouse is RVU120, a CDK8/19 inhibitor with activity in both hematologic and solid tumor cancers currently undergoing multicenter, international testing for AML and TNBC, respectively. With data reported as recently as EHA 2022, pivotal phase II testing will commence in early 2023. As for the platform, with a dual focus on immune-oncology and synthetic lethality—Galapagos wants to take it for a spin, as does Merck, and Ryvu just inked a deal with Exelixis. Give a listen to Ryvu CEO Pawel Przewiezlikowski for all the details…2022-08-0531 minLifeSci Partners PodcastAdvances in gene therapy delivery: a non-viral pDNA platform that harnesses the power of IL-10Using cytokines therapeutically is like firing a shotgun at range – for sure you will hit your target, but off-target effects are likely, if not certain. To hit your target exclusively you have to get close. Delivering a proprietary version of the chronic inflammatory cytokine IL-10 encoded on a proprietary plasmid, injected locally, gets you really close. Using their non-viral, non-integrating vector, Xalud Therapeutics is exploring the use of IL-10 for osteoarthritis (FDA fast tracked), and other chronic inflammatory conditions, including ALS, MS, and neuropathic pain, with data from over 300 OA patients already in hand.2022-07-2932 minLifeSci Partners PodcastA Pioneer of PARP Inhibition has a New DNA Damage Repair (DDR) PlatformAn inch wide and a mile deep—that’s the sort of expertise CSO of Artios Pharma, Dr. Graeme Smith, brings his benchtop. Since his time at Cambridge, Smith has been laser focused on DDR mechanisms, first elucidating, and then translating those observations to create the PARP inhibitor drug, Lynparza. Developed at Kudos Pharma, and later, AstraZeneca, hear Smith recall his “aha” moment for this first-in-class blockbuster drug, as well as his descriptions of his two new DDR-targeting, clinical stage assets developed at Artios that leverage his knowledge of novel DDR pathways—including those that will overcome resistance to PARP inhib2022-07-2631 minLifeSci Partners PodcastTeclison’s cancer immunotherapy-enhancer, TEC-001, shows efficacy in all-cause hepatic tumorsHypoxia is the key. TEC-001 is a prodrug selectively activated in hypoxic environments, such as that induced by the long-known technique called trans-arterial embolization, a procedure that shuts off blood supply to tumors and thereby creates a low-oxygen, hypoxic environment. Delivered directly to the tumor bed through a tumor-feeding artery, hypoxia-activated TEC-001 then converts into free radicals that cause so-called immunogenic cell death (necrosis, as opposed to apoptosis) which enables immune cells—boosted with immunotherapy—to seek out and destroy tumor cells both locally, and throughout the body. CEO Ray Lee, M.D., Ph.D., explains.2022-07-1542 minLifeSci Partners PodcastiBreathe it in: Inhalable drug delivery with the iSPERSE platform, from PulmatrixA car is a very efficient delivery system until you can’t find a place to park, or the spot you find is nowhere near where you wanted to go. For medicine, getting to the right place, and getting there in time is critical. With the iSPERSE platform you can reformulate known drug entities—compounds that have already been de-risked—for fast-acting pulmonary distribution using most any inhaler device. Listen to the POC work already in hand for migraine, and COPD as described by Pulmatrix CEO Ted Raad.2022-07-1246 minLifeSci Partners PodcastP53 Reactivation via MDM2 Inhibition with Milademetan: Phase 3 Data in 1H 2023 (Rain Therapeutics)MDM2 is a key regulator of p53, the protein responsible for tumor suppression and apoptosis — an intractable, yet undruggable target. Previous attempts to drug MDM2 have been met with significant toxicities issues. The MDM2 oral inhibitor milademetan has the potential to address these issues and in doing so may open the door to treating multiple tumor types, as identified by standard molecular testing. Indeed, studies with milademetan have demonstrated promising preliminary results in liposarcoma. Let the Wall Street veteran, CEO Avanish Vellanki, walk you through the RAIN.2022-07-1136 min
LifeSci Partners PodcastP53 Reactivation via MDM2 Inhibition with Milademetan: Phase 3 Data in 1H 2023 (Rain Therapeutics)MDM2 is a key regulator of the holy grail of oncology, the tumor suppressor called p53—an intractable, as yet undruggable target. But you can drug MDM2, and a number of companies have, only to walk away due to unacceptable toxicity. The MDM2 inhibitor milademetan has solved that problem, and in doing so opened the door to treating multiple tumor types, as identified by standard molecular testing. Indeed, cancers as different as liposarcoma, and Merkle Cell are already responding to this drug. Let the Wall Street veteran, CEO Avanish Vellanki, walk you through the RAIN.2022-07-0836 minLifeSci Partners PodcastAn anti-PD-L1 Antibody Given Subcutaneously: Envafolimab, by Tracon PharmaThe only people that like infusion suites are those who own them. Payers don’t like them. Patients hate them. But for many drugs, due to their molecular nature there is simply no choice, and this has been the case with the class of drugs known as checkpoint inhibitors—until now. Now there is Envafolimab, a novel anti-PD-L1 antibody from Tracon Pharma with a low volume, subcutaneous administration that is already being tested in the clinic in multiple indications. Listen in as CEO Charles Theuer describes his licensing strategy that brought Envafolimab, as well assets targeting CTLA-4, CD73, and DNA...2022-07-0144 minLifeSci Partners PodcastTwo conditions, one drug: working to relieve chronic cough in IPF, and debilitating itch in prurigo nodularis with the opioid-receptor-targeting drug, HADUVIOBy way of an exquisite toggling of activity, HADUVIO stimulates one opioid receptor (kappa) and blocks the activity of another (mu) while avoiding the engagement of the third (delta). The objective of this combination of receptor activity is to decrease chronic cough due to Idiopathic Pulmonary Fibrosis, or severe itch due to Prurigo Nodularis. Phase II data are available for both development programs, which CEO Jennifer Good has proudly shared—along with a story of how Trevi got its name…2022-06-2742 minLifeSci Partners PodcastSpecial Delivery Platforms: pH-activated and STING activating polymeric micelles from OncoNano MedicineIf the pandemic taught us nothings else, we’ve learned the critical importance of having a dependable system for delivery. OncoNano offers two such systems (read: platforms). The first, ON-BOARD, is a polymeric micelle that delivers its therapeutic payload only in the acidic environment of a tumor bed. The second, OMNI, consists of a polymer that in itself stimulates the immune-activating STING pathway, and which can further be loaded with other STING agonists, or, potentially, other mechanistically relevant oncology agents. POC phase II trials are underway…2022-06-2341 minLifeSci Partners PodcastPhase II POC for Immutep’s LAG-3 drug, eftilagimod alpha: ASCO data, and an introduction to CEO Marc VoigtAlong with the first-ever approval by the FDA of a so-called checkpoint inhibitor, the anti-CTLA-4 drug Yervoy, in 2001, came vindication; the treatment modality of immuno-oncology (IO) had arrived. Anti-PD-1 drugs soon followed with even greater—far greater impact. But then came some failures, and the presumed bright future of other IO assets began to dim. Until now. The first LAG-3-targeting drug was recently approved, and as of ASCO 2022, Immutep’s LAG-3 asset is poised to replace IO/chemo in the front-line setting for NSCLC. Hear CEO Marc Voigt parse the data, and describe the development program going forward.2022-06-2239 minLifeSci Partners PodcastInducing Immune Tolerance in Autoimmunity, Gene Therapy, and Beyond: The ImmTOR® Platform, from Selecta BiosciencesThere’s no point in receiving a gift you can’t keep, be it a pony, or a therapeutic. For the latter to be effective it must be retained, yet the immune system can’t discriminate between friend or foe; there is only you, and not you, and not you is simply not tolerated. Enter ImmTOR®, a nanoparticle technology that aims to tolerize the immune system to the target of choice – a gene therapy, a biologic, or in cases of autoimmunity – you. With buy-ins from the likes of Takeda, Sarepta, Sobi and AskBio, it’s worth it to find out more abou...2022-06-1735 minLifeSci Partners PodcastDosing more than Skin Deep: A Transdermal Drug Delivery Platform from Dyve BiosciencesThere’s nothing new about transdermal delivery of drugs—patches, gadgets, and solvents abound—but each has physical limitations, and the drugs themselves may not be amenable to a particular approach. Enter a novel drug formulation platform by Dyve Biosciences. Delivered in what appears to be a cosmetic cream, Dyve has two POC clinical trials underway: Gout, to test local delivery of a drug; and cancer, testing the same drug that can only be delivered through the skin, and targeting the tumor microenvironment (with a buy-in from Moffitt Cancer Center). CEO Dr. Ryan Beal explains…2022-06-1041 minLifeSci Partners PodcastLocation, Location, Location: Delivering Your IO Asset Directly to the Lymph Node with AmphiphileIn pharmacology, getting your drug to where it’s needed is everything. In immunology, to elicit an immune response that location is often the lymph node, and the point of delivery are antigen presenting cells. Amphiphile, from Elicio, can make that happen. Whether the cargo is DNA, a peptide, or a small molecule, once linked to the Amphiphile moiety, the construct is taken up by the lymphatic system. First asset in the clinic? A multiple antigen therapeutic for mKRAS.2022-05-1331 minLifeSci Partners PodcastMaking sure there’s not a dry eye in the house with Tyrvaya®, from Oyster Point PharmaInnovation can sometimes be counterintuitive, as in the case with Tyrvaya, a drug approved in 2021 for the signs and symptoms of dry eye disease that is a nasal spray. And how does that make sense? Well, it makes sense because Tyrvaya ®, a cholinergic agonist to treat the underlying, and sometimes debilitating disease. Hear Dr. Jeffrey Nau, ophthalmology expert and CEO of Oyster Point explain…2022-05-0644 minLifeSci Partners PodcastThe sweet spot (and the market) between the adaptive & innate immune response: Allogeneic Natural Killer T cells (NKT) from AthenexThe allure of allogeneic “off-the-shelf” adaptive cell therapy (ACT) is obvious – by definition, the treatment is immediately available, and due to the nature of batch manufacture versus the one-off creations of an autologous ACT, it will very likely be cheaper. The question remaining is what cell type is best to use for clinical efficacy – T cells of the adaptive immune system, or natural killer (NK) cells of the innate system, OR, just maybe, a cell that does both – the CAR NKT cell therapy, from Athenex. Hear Dr. Daniel Lang, President of Athenex Cell Therapy, explain how this is possible.2022-04-2229 minLifeSci Partners PodcastA Rare (Disease) Opportunity: Amolyt Pharma – Targeting Orphan Diseases of the Endocrine SystemHaving focused on endocrine disorders since grad school, first at the bench and later in the board room, Dr. Thierry Abribat founded and became the CEO of EU-based Amolyt Pharma because he wanted to have a “social impact” – he wanted to make a difference. With two clinical stage, biologic assets in hand (and an orphan drug designation) Abribat is hoping to address the serious unmet needs of patients with hypoparathyroidism and acromegaly.2022-04-1436 minLifeSci Partners PodcastA clinical-stage biotech company developing a targeted oral small molecule for synergistic combinations with SOC -that's Cardiff Oncology.Everyone is excited about KRAS, the “undruggable” target that now has a drug. However, that drug only hits one specific, rather rare KRAS mutation, leaving the vast majority of patients with KRAS mutant variants who, after exhausting standard of care (SOC), are left without any effective treatment options. So, what if you had a drug that hit just downstream in the KRAS pathway, and further, was synergistic with SOC – wouldn’t that serve all such patients? Yes. Yes, it would. That drug is called Onvansertib, from Cardiff Oncology.2022-03-2531 minLifeSci Partners PodcastToday’s Oncology Play: Global Reach, Clinical Stage Assets, and a Revenue Stream – AntengeneHear how Jay Mei, MD, PhD, went from his benchtop years at the NIH to a blockbuster launch at Celgene (think, Revlimid, after stints at Novartis and J&J along the way) – to spearhead the multi-asset juggernaut that is the oncology company, Antengene. From it’s “license and build” beginnings, to the advent of in-house programs (15 assets in all) Antengene is poised to hit multiple oncology targets, from a small molecule ERK 1/2 inhibitor, to a bispecific for PD-L1/ 4-1BB. And did I mention they have a global license, and are expanding indications for XPOVIO? Give a listen…2022-03-1840 minLifeSci Partners PodcastDyadic International: Helping to produce biologic vaccines and drugs rapidly, in large quantities and at low cost for a global population.Proteins designed as drugs – the so-called biologics – sparked a medical revolution, but it has come at an extraordinary cost: less than 2% of Americans use these drugs, yet they account for 40% of total spend on prescription medications. Something’s got to give. Mark Emalfarb of Dyadic thinks that something is manufacturing, and his something is C1 – a protein manufacturing platform, and cell line that can produce biologics cheaper and faster than anything out there. Unconvinced? Give a listen.2022-03-1138 minLifeSci Partners PodcastDifferentiated Delivery with DPX® - a Versatile Technology for Immuno-Oncology by IMV Inc.Having the ability to activate a precise, robust and persistent immune response to kill cancer cells is what IMV is all about. Using its DPX delivery technology, IMV’s immunotherapies are easy and cost-effective to manufacture. With promising clinical data now available, their lead compound is well tolerated and effective in several cancer indications including solid cancers (ovarian and bladder cancers) and DLBCL (lymphoma). What else is cooking at IMV? Former professional chef, and IMV CEO, Andrew Halls gives us a taste…2022-03-0337 minLifeSci Partners PodcastDeveloping Drugs for Rare Diseases: Pointers and PitfallsThere are approximately 30 million individuals in the U.S. currently living with one of at least 7,000 rare diseases. The National Organization for Rare Disorders estimates that more than 90% of these patients are still without an FDA-approved treatment. Dr. Jane Larkindale, VP of Clinical Science at PepGen, Inc. is looking to change that, and she has both the experience and passion to show you how.2022-02-2834 minLifeSci Partners PodcastTargeting Cancer and Fibrosis. Galecto aims to help patients with their first-in-class, small molecule drugs in clinical developmentA scar is proof you survived – a good thing. Uncontrolled scarring, called fibrosis, is a threat unto itself (think cirrhosis) or an impediment to clinical intervention (think macrophages, T-cells and cancer). Mechanisms that drive both involve the molecule, Gal-3, and an enzyme, LOXL2. The mission of Galecto is drugging these targets with small molecule, first-in-class inhibitors. Hear how Galecto’s CEO, Dr. Hans Schambye, made their mission his own.2022-02-2434 minLifeSci Partners PodcastMapping Neoantigens in Cancer with Genocea’s ATLAS: What to Include, and What to Avoid in Your Cancer TherapyIn oncology, the field of neoantigen prediction is rife with proprietary mathematics for homing in on the best antigens for T cell activation. Only one neoantigen platform, ATLAS, from Genocea, tells you not only about what activates, but also what antigens/epitopes suppress that T cell activity – so called, “inhibigens”. With his platform recently validated in Cancer Discovery, Chip Clark, CEO of Genocea, explains the investment opportunity that is ATLAS.2022-02-1835 minLifeSci Partners PodcastEvery tumor is a deadly frontier, and to survive it you need a personalized, therapeutic path forward. Enter the AI-centric guidance of Evaxion’s, PIONEEREvery cancer neoantigen prediction platform has lots and lots of math – the PIONEER platform, from the Danish company, Evaxion, has data. In a phase I/IIa study in metastatic melanoma the ORR was 67%, and two patients with stable disease converted to complete responders. Investors take note, because Merck sure did… Dr. Lars Wegner, CEO of Evaxion fills in the details.2022-02-1137 minLifeSci Partners PodcastWater, Water, Everywhere – Innovations in Treating Diuretic-Resistant Fluid Overload: Sequana MedicalNot enough fluids? Drink more. Too much fluid – entirely different, far more complex problem. From the systemic swelling caused by congestive heart failure to the localized ascites caused by cancer, or NASH, Sequana Medical has developed novel approaches to drain the fluid away when diuretics are no longer effective. The results are greatly improved clinical outcomes and quality of life for patients, and significant cost savings. Ian Crosbie, CEO of Sequana Medical, Oxford graduate, and long-time financial-world veteran, explains it all.2022-01-2134 minLifeSci Partners PodcastModulation of NMDA Receptors for Pain and CNS Disorders: The Middle Way – that’s AptinyxTurning a biological process on or off is like flipping a light switch. However, these approaches often come with serious side effects that can limit therapeutic utility. For this reason, treating certain types of CNS disorders like chronic pain, PTSD, and cognitive impairment requires a more nuanced modulatory approach to restore normal brain function. Listen in as Aptinyx’s newly minted president & CEO Andy Kidd, MD explains how the company is taking a novel approach to NMDA receptor modulation to help create a platform of small molecules aimed at restoring normal brain balance to address a host of serious ne...2022-01-1433 minLifeSci Partners PodcastImmatics: Engineering the Right T Cell Receptor for Shared Tumor-Associated TargetsHarpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries in immunology into highly innovative immunotherapies to impact the lives of cancer patients.2022-01-0634 minLifeSci Partners PodcastCaptor Therapeutics: Top Grades for Degrading Pathologic Proteins in Oncology and Autoimmune Disease: Captor TherapeuticsHear how Captor Therapeutics became a Swiss/Polish public biotech company run by a Scotsman –as told by 30-year healthcare industry veteran and Captor’s CEO, Dr. Tom Shepherd. That’s one great story – another is how Captor’s targeted protein degradation platform will stick it to the competition with their ligase library, and proprietary molecular glues and bifunctional degraders...2021-12-1730 minLifeSci Partners PodcastDiscovery Platform for Small Molecule mRNA Drugs like no other: mRNA Lightning, from Anima BiotechFor the computer expert/CEO of Anima, Yochi Slonim, it’s all the same – lots of instructions and lots of code. It could be code for AI, it could be codons for the translation of proteins. With the elucidation of unique codon pairings by mRNA Lightning, Slonim can turn expression on or off, or up or down, depending on the therapeutic need, like say, in CNS disorders. Eli Lilly has taken notice. So has Takeda. You might want to give a listen…2021-12-1033 minLifeSci Partners PodcastSeeing clearly where the sun don’t shine: A game-changing technology in GI endoscopy from Motus GIYour GI team can’t help you if they can’t see what’s wrong. An endoscope might encounter clotted blood in the esophagus from chronic bleeds, or remaining stool in the colon after an insufficient prep. Either way, it would be nice to have a device that clears the way for precise imaging. The Pure-Vu® System, by Motus GI, offers both, and at a savings of time, and money. In this podcast, Tim Moran, CEO of Motus, tells us all about it.2021-12-0334 min
PRWeek Coffee BreakCoffee Break with Matt Middleman, founder + CEO of LifeSci CommunicationsCoffee Break topics:- The origin story of LifeSci Communications.- What is the role of the doctors and scientists in the PR firm?- How has COVID-19 impacted the success of LifeSci Communications?- Impactful work done over the years that stands out.- The world developing in front of Middleman’s eyes where science has become a topic of mainstream media interest.- New drug manufacturing in a post COVID-19 world.- Strategy around employees coming into the office.- The ne...2021-12-0114 minLifeSci Partners PodcastGBS Inc: A Saliva Test for Diabetes Monitoring: An inside look at the Glucose Biosensor TechnologyThree facts: 1) World Diabetes Day is November 14th, which marks the 100th anniversary of the discovery and isolation of insulin. 2) There are an estimated 463 million diabetes patients worldwide – and that number is rapidly rising. 3) Access to care remains a major hurdle for diabetes patients, but today GBS is developing an affordable, smartphone-compatible, needle-free glucose monitor. Endocrinologist/ Interim CEO, Dr. Steven Boyages is here to tell you all about it.2021-11-1531 minLifeSci Partners PodcastLean and mean, outsourcing oncology machine: Anixa Biosciences, Inc.He’s got patents, patience, and a plan – and a five-year runway to execute. Listen in as Dr. Amit Kumar, CEO of Anixa Biosciences, tells a tale of novel vaccines for breast, and ovarian cancer, and a new kind of CAR-T therapy – also for ovarian cancer – called a CER-T: a Chimeric Endocrine Receptor T cell. Is it worth your investment? Cleveland Clinic, Moffit Cancer Center, and investigators at NIH seem to think so…2021-11-1228 min
LifeSci BeatWelcome to LifeSci Beat!Welcome to our introductory episode of the LifeSci Beat.Here, we briefly cover our goals and motivation for the podcast and introduce our hosts: Shubham Chatterjee, Jaclyn Kawwas, and Kevin Nguyen. Stay tuned for our first interview, coming soon!2021-11-1002 minLifeSci Partners PodcastNOXXON: Targeting the Chemokines of the TME to enhance Cancer TherapiesFrom a doctorate at the SALK Institute overlooking La Jolla Cove, to an MBA from INSEAD, the world-leading business school located near Paris, NOXXON CEO Aram Mangasarian knows his way around different environments. Now he’s focused on tackling the tumor micro-environment (TME) and targeting the chemokines that drive tumor immunosuppression. Lead asset, NOX-A12, has generated exciting early results in some of the most challenging tumor types: pancreatic cancer and glioblastoma.2021-11-0527 minLifeSci Partners PodcastFemasys Inc: Putting the Focus on Women’s Reproductive HealthAfter spending the first half of her career developing medical devices for others, Kathy Lee-Sepsick, founder, and CEO of Femasys sets out to address the often-overlooked needs of a woman’s reproductive health – and she can’t be more passionate about the mission. Not only is Lee-Sepsick the company’s founder and CEO, but she’s also the inventor of Femasys’ two key reproductive health technologies: FemBloc, a permanent form of birth control that is much less invasive, and less expensive than the current standard of care, and Femaseed, a technology targeted to help women with reproductive difficulties conceive.2021-10-2929 minLifeSci Partners PodcastTo Find the best Antigens for Cancer, or COVID, Gritstone bio has the EDGE™From a famous pub in Oxford to a lab on California’s coast, Gritstone founder, and CEO Dr. Andrew Allen tells the story of how his dream, inspired by a legend in cancer immunotherapy, became the reality that is Gritstone bio, a company developing both off-the-shelf and personalized vaccines for cancer – and now COVID – with antigens discovered by their proprietary, machine learning platform, EDGE™.2021-10-2236 minLifeSci Partners PodcastVincerx Pharma: From Pharmacyclics to Cyclins – The Will and the WayListen in while Vincerx CEO, Dr. Ahmed Hamdy shares his experience with life-changing events, a date with the cancer target CDK9, and the utterance of every investor’s favorite magic word: “Platform.”2021-10-0832 minLifeSci Partners PodcastRepairing Organ Damage – Angion BiomedicaCombining his medical expertise with his business acumen, Angion’s CEO, Dr. Jay Venkatesan, is focused on meaningfully improving both health outcomes for patients in need and economic outcomes for the healthcare system. After successes at McKinsey, Bain, Ayer Capital, and Alpine BioVentures, Dr. Venkatesan is now seizing on what he describes as a rare opportunity to lead Angion, whose products have the potential to transform care for millions of patients. He was originally attracted to Angion – a 20-year old biotech company – as an investor due to its HGF mimetic technology being developed to treat acute organ injuries, including acute...2021-09-3036 minLifeSci Partners PodcastExperience, Passion, and a Plan: Vera Therapeutics, Dr. Marshall Fordyce takes us from the bedside to the boardroom in his mission to treat autoimmune diseaseDr. Marshall Fordyce, CEO of Vera Therapeutics still treats patients – it is a calling he will always hear. It took him to the bedside at HIV clinics in the East to leadership roles in developing life-saving drugs at Gilead in the West. Entrepreneurship flowed from experience, and Vera Therapeutics came to be. Focused on nephrotic autoimmune disease, hear how Fordyce brought his heart and mind to this urgent unmet need.2021-09-2427 minLifeSci Partners PodcastA Promising Repurpose: Tenax Therapeutics Tests the Cancer Drug Imatinib in Pulmonary Arterial HypertensionChristopher Giordano, MS, explains how an American English major studying at Oxford University lucked into marrying a Welsh girl he convinced to move to North Carolina’s Research Triangle – a hotbed of literary studies. From that beginning – somehow – Giordano got a "real job" in drug development, rising through the ranks to become president of a business unit in healthcare giant, IQVIA, and eventually, CEO of Tenax. He tells me the Tenax name comes from the word "tenacity". Of this, I have no doubt. Now listen to him spin imatinib into gold for Pulmonary Arterial Hypertension (PAH).2021-09-1730 minLifeSci Partners PodcastMedicenna Therapeutics: Reining in the Fire: Taming IL-2?You can fight fire with fire – it’s a thing. The problem is having anything left to salvage after the fire is out, and thus the conundrum of IL-2: the cytokine’s ability to supercharge T cells against cancer has been known for years, but the problem has always been its profound toxicity. Fahar Merchant, CEO of Medicenna explains how directed evolution has allowed him to turn the agent of wildfires into a tool for a controlled therapeutic burn.2021-09-0934 min
LifeSci Partners PodcastImmutep: No Longer Left Behind: LAG-3 Hits the Clinical (Late) StageThe field of cancer immunotherapy exploded in 2011 with the FDA approval of an utterly novel, so-called “checkpoint” drug, the anti-CTLA-4 agent, Yervoy. The fires of that first-in-class success ignited a drug development rocket – the approval of the checkpoint-targeting drugs Keytruda and Opdivo occurred shortly thereafter. But then came a lot of dark, cold space. Until now. Frederic Triebel, the founder of Immutep, explains how his discovery – the checkpoint molecule called LAG-3 – is finally ready to reach for the stars.2021-08-2728 min
So You Got A Lifesci Degree24: The Episode to End All EpisodesHere is the FINAL episode of So You Got A Lifesci Degree!! Farida and Lisa reflect on their podcasting experiences and play a second round of "How Well Do You Know Your Co-host."
Episode transcript
Resume Worded
Rate us on Apple Podcasts
Check out our Anchor webpage
Email us at soyougotalifescidegree@gmail.com
Music copyright notice: No Regrets (2015) - Royalty-Free Music by https://audiohub.com2021-08-2342 minLifeSci Partners PodcastCompugen Pioneering DNAM axis in cancer: TIGIT and PVRIG – Synergistic CheckpointsTo the oncologist, human physiology is a riot of redundancies, and treating cancer is a game of whack-a-mole – target one mechanism, another pops up. Anat Cohen-Dayag, scientist and CEO of Compugen has known this for years. However, to bring her expertise into the clinical realm, she needed to transform her company from a service provider of computational target discovery, into a savvy team of scientists/clinicians poised to enter the blockbuster field of cancer immunotherapy checkpoints.2021-08-2034 minLifeSci Partners PodcastHERVs and Nerves: Targeting the viral origins of neurodegenerative diseaseGeNeuro's CEO, Jesus Martin-Garcia, a consummate technology entrepreneur, tells his business journey from the birth of telecoms, to the advent of online grocery shopping, to his support and exploration of the final frontier in healthcare - biotechnology. GeNeuro is using human endogenous retroviruses (HERVs) to treat autoimmune diseases, including MS, ALS, and the lasting neurological symptoms of COVID-19.2021-08-1329 minSo You Got A Lifesci Degree23: Science Writing (with Dr. Anna Clemens)This week, we talk to Dr. Anna Clemens about the field of SCIENCE WRITING!! Anna is a scientific writing coach who has herself been published in popular science magazines like Scientific American, and has helped researchers get published in high-profile journals like Nature Communications. Anna tells us about the different forms of science writing, the realities of being a freelance science writer, and things to remember in your own writing!
Episode transcript
Resume Worded
Anna's free 1-hour interactive training for researchers
Anna's Twitter: @scientistswrite
2021-08-0938 minLifeSci Partners PodcastAre iNKT cells the next frontier in cancer treatment?Can T cells be leveraged as a cancer therapeutic? Check. How about natural killer (NK) cells? Check. Now meet invariant natural killer (iNKT) cells – a potentially game-changing tool to reprogram the innate and adaptive immune system to recognize and attack tumors. In this episode of the Benchtop Bios Podcast, leading life science entrepreneur and former Executive Director at Bristol-Myers Squibb, Dr. Ian Walters – now CEO of Portage Biotech – highlights the role iNKT cells play in activating the immune system and how Portage is leveraging these cells to advance novel cancer treatments.2021-08-0635 minLifeSci Partners PodcastPixium Vision SA: An Eye Towards the Future: High Tech Treatment for Dry AMDThere are no approved treatments to treat dry macular degeneration – a disease of the eye that can lead to eventual blindness. The standard of care for these patients consists of functional/behavioral training to acclimate the patient to their progressive, incurable vision loss. Lloyd Diamond, CEO of Pixium Vision, is convinced that much more can be done. Thus, the advent of Prima: Pixium’s bionic eye. 2021-07-3032 minSo You Got A Lifesci Degree22: Midwifery (with Dr. Elizabeth Darling)Today's episode is about MIDWIFERY!!! We chat with Dr. Elizabeth Darling, a registered midwife and the Assistant Dean of Midwifery at McMaster University, about the details of this growing profession. What is a midwife? Is that different from a doula? What is it like being on call? We have answers!
Episode transcript
Resume Worded
Roof squirrel
McMaster Midwifery Research Centre
Support us on Patreon
Rate us on Apple Podcasts
Check out our Anchor webpage
2021-07-2550 minLifeSci Partners PodcastArcellx: Plug and Play CAR-T: Modular ImmunotherapyFrom a training at the bedside to a benchtop at the NIH, to the realities of life on the Dark Side, Arcellex CMO, Dr. Chris Heery speaks of his passion of all things immunologic, and in particular, the Arcellx platform that can target, activate, and control a CAR-T cell with their proprietary SparX plug. He also recalls the time he had to face a room full of angry biotech investors (N=50 or more): a textbook example of grace under fire.2021-07-2335 minLifeSci Partners PodcastA Time for Cocktails. Polytope: A Potential Treatment for Covid-19Dr. Jennifer Bath, an expert in antibody discovery, as well as translational work in infectious disease, explains why leaving a tenured professorship was a price worth paying to become the CEO of ImmunoPrecise Antibodies (IPA). Under her leadership, and with B Cell Select, a proprietary discovery platform at her command, IPA is developing a therapeutic antibody cocktail called, Polytope, that has the potential to not only treat current strains of Covid-19, but also emerging variants. She also answers the critical question: Which is more difficult, antibody discovery, or irregular verb forms in French (hint: French is hard…)2021-07-1233 minSo You Got A Lifesci Degree21: Museum Curation (with Dr. Sebastian Kvist)This week's guest is Dr. Sebastian Kvist, an Associate Curator at the Royal Ontario Museum AND an Assistant Professor of Ecology and Evolutionary Biology at the University of Toronto! Sebastian has been working as a curator at the ROM for over six years, and is in charge of the invertebrate collection. During this time, he has developed quite the collection of knowledge about, well, collection and knowledge!
Episode transcript
Resume Worded
Grad squirrel
Kvist lab site
ROM online invertebrate collection2021-07-1239 minLifeSci Partners PodcastGetting the Bugs out of Alzheimer’s: A New Therapeutic ApproachCortexyme CEO, Casey Lynch, discusses her life-long passion for finding treatments for neurodegenerative diseases in general, and Alzheimer’s in particular. She tells how her experience over the years, in different labs, and in different companies taught her that the science behind proposed Alzheimer’s interventions was missing the forest for the trees, and that an entirely different hypothesis suggested that one of the root causes of Alzheimer’s is a history of infection with a bug that causes periodontal disease: P. gingivalis. Sound far-fetched? Well, give a listen…2021-06-3021 minLifeSci Partners PodcastSwitching it Up: Medigene Charts a New CourseMedigene CEO, Dolores Schendel, takes us from her Midwestern roots to the helm of Bavaria’s Medigene AG. Along the way, she explains how her training at the hands of immunotherapy pioneers led to her recent move to deploy a novel molecular switch which protects and energizes Medigene’s TCR-T cells in their attack on solid tumors. (Plus, hear her talk about winning the prestigious Bavarian Order of Merit! For what, you ask? Well – give a listen…)2021-06-2831 minLifeSci Partners PodcastCancer Treatment Goes Viral Featuring: Dr. Matt Coffey, CEO Oncolytics BiotechDr. Coffey explains how a phenomenon first observed over a 100 years ago – that a systemic infection can cure cancer – became the blanket term for a treatment modality bearing his company’s name. From being a lab rat studying reovirus one day, to a company co-founder the next, Coffey’s rise through the corporate ranks (he started out as VP of Product Development), and his pursuit of the scientific secrets that revealed the true activity of his lead asset (hint: lysing tumor cells ain’t it) set Oncolytics on the path to achieving medicine’s ultimate goal: teaching a patient’s immune syste...2021-06-1847 minLifeSci Partners PodcastBiomX: A Real Phage-TurnerBiomX co-founder, Jonathan Solomon, gained his early scientific training in physics, and electrical engineering during a ten-year stint in an Israeli army special forces unit – which he can’t really talk about. But what he can talk about is how – with his taste for adventure, a Harvard MBA, and a famous Israeli scientist for a mother – he became the Chief Executive Officer of Biomx, a publicly held company that is harnessing naturally occurring phage to kill pathogenic bacteria in a broad variety of disease settings.
Topics on the show include:
Introduction to phage biology
What it took to...2021-06-0429 minSo You Got A Lifesci Degree20: Space Life Science Research (with Dr. Gioia Massa)Our episode this week is with Dr. Gioia Massa, a Project Scientist at NASA Kennedy Space Centre! Gioia has worked at NASA for the past 10 years, improving the cultivation of crops in space for future missions. She talks to us about the branches of space life science research, the challenges of growing plants in space, and how she landed a sweet job at NASA!
Episode transcript
Resume Worded
Support us on Patreon
Rate us on Apple Podcasts
Check out our...2021-05-3149 minSo You Got A Lifesci Degree19: Environmental Law (with Dr. Dianne Saxe)This week's episode is with Dianne Saxe, an internationally recognized environmental lawyer and Deputy Leader of the Green Party of Ontario. Dianne has over 40 years of experience in environmental law, working for both the Government of Ontario and her own law boutique. She tells us about what it really means to be an environmental lawyer, and offers an honest opinion about job availability in the field.
Episode transcript
Hexagons are the Bestagons
Saxe Facts
Vote for dianne
Green Economy...2021-05-1744 minLifeSci Partners PodcastNK cell biology no longer stands for “Not Known”: Michael A. Caligiuri, M.D., Chief Medical Officer, and Co-founder of CytoImmune TherapeuticsDr. Caligiuri describes his journey from being a liberal arts major at a college in upstate New York, to being a Stanford trained MD, to his current position as President of City of Hope National Medical Center. Along the way Caligiuri shares his thoughts on training to be a hematologist in the late ‘80s – at a time when there were no curative therapies, and such a calling was daunting at best – to his finding a cherished mentor that put him on the road to becoming one of the top NK cell experts in the world.2021-05-1239 minSo You Got A Lifesci DegreeSAMPLE MINICAST! (Honeypot ants & ant beetles)SURPRISE!!! We're releasing one FREE MINICAST for your sampling pleasure!
Our minicasts are 5 - 10 minute BONUS episodes released alongside each main episode! In them, we chat about our "shenanigan" of the week - squirrel stories, electrocution by grape, captcha struggles, and more!
If you'd like to gain access to ALL our minicasts (and also support the show) you can become a Patreon member for $1/month!
Click here to support us! We would appreciate it so much! :)2021-05-0908 minSo You Got A Lifesci Degree18: Biomedical Product Management (with Tashfina Rabbani)Join us this week for a lovely chat with Tashfina Rabbani, a Senior Product Manager of the Rare Diseases Portfolio at Ipsen! Tashfina tells us about her experience in devising marketing strategies for pharmaceutical products. What even is product management? Why is there a photo of a woman in a sunflower field on the back of my toilet stall? We have the answers!
Squirrel video
M. Biotech Program
Bum Run
Resume Worded
Support us on Patreon
Rate us on Apple Podcasts2021-05-0355 minSo You Got A Lifesci Degree17: Sustainability Program Management (with Eric Meliton)This week's episode is with Eric Meliton. Eric was the program manager at the Toronto and Region Conservation Authority (TRCA) for seven years, and has recently transitioned to being the Manager of Sustainability at Laurier University. He talks to us about working with businesses to implement sustainable policies and his experience in wastewater management (yummy)!
Cloudberry photos
Eric’s Twitter
Eric’s LinkedIn
Support us on Patreon
Rate us on Apple Podcasts
Check out our Anchor webpage
Email us at s...2021-04-1950 minSo You Got A Lifesci Degree16: Undergraduate Course Coordinator (with Alastair Tracey)Join us this week as we chat with the one and only Alastair Tracey! Alastair is the Level II Undergraduate Coordinator in the Department of Biology at McMaster University. Listen to discover the method behind the madness of undergraduate course coordination!
Alex Honnold swinging
Support us on Patreon
Rate us on Apple Podcasts
Check out our Anchor webpage
Email us at soyougotalifescidegree@gmail.com
Alpaca tours
Alpaca products
Kickin’ Back Alpaca Ranch Facebook
...2021-04-0539 minSo You Got A Lifesci Degree15: Half Birthday ExtravaganzaA special episode this week! In honor of the podcast's half birthday, Lisa and Farida play a game of "How Well Do You Know Your Co-host". Who is most likely to laugh at the wrong moment? Lock themselves out of the house? Become ruler of the world? Lisa and Farida have the answers!
Support us on Patreon
Rate us on Apple Podcasts
Check out our Anchor webpage
Email us at soyougotalifescidegree@gmail.com
Alpaca tours
Alpaca products
Kickin’ Ba...2021-03-2239 minSo You Got A Lifesci Degree14: Specialist Pharmacist (with Rishika Sharma)This week we chat with Rishika Sharma, a Specialty Pharmacist at Bayshore Healthcare. Rishika edumacates us on how specialty pharmacists focus on medications for certain groups of illnesses, such as cancer. Unlike your local neighborhood pharmacist, Rishika spends little time interacting with patients behind the counter, and more time fulfilling complex prescriptions!
Study bunny
Study bunny IG
Study bunny FB
Study bunny Twitter
Alpaca tours
Alpaca products
Kickin’ Back Alpaca Ranch Facebook
Kickin’ Back Alpaca Ranch Inst...2021-03-0835 minSo You Got A Lifesci Degree13: Environmental Economist (with Ben Moy)This episode we chat with Ben Moy, an Economist at Environment and Climate Change Canada (ECCC). Ben performs economic analysis of policies implemented by the ECCC. He's currently working on policies involved in a post-pandemic "green recovery" plan!
Climate change song
Climate change comic
Study bunny
Study bunny IG
Study bunny FB
Study bunny Twitter
Alpaca tours
Alpaca products
Kickin’ Back Alpaca Ranch Facebook
Kickin’ Back Alpaca Ranch Inst...2021-02-2256 minSo You Got A Lifesci Degree12: Professor Shenanigans (with Doc Roc)This week we chat with Dr. Jonathan Stone (a.k.a. Doc Roc), an Associate Professor in the Department of Biology at McMaster University. Doc Roc tells us stories of his adventures in Sweden, a misrepresentative tardigrade species, and peeing on sea urchin wounds!
Study bunny
Study bunny IG
Study bunny FB
Study bunny Twitter
Tardigrade paper
Support us on Patreon
Rate us on Apple Podcasts
Check out our Anchor webpage
Email...2021-02-0859 minSo You Got A Lifesci Degree11: Sweet Prince of Careers (with Jared Kunar)This episode, we chat with Jared Kunar from McMaster University's Science Career and Cooperative Education Office (SCCE). Jared tells us about how he helps students develop job search techniques, create targeted resumes and cover letters, and figure out where the heck their life is going!
SCCE Instagram: https://www.instagram.com/mcmasterscce/
SCCE Website: https://science.mcmaster.ca/scce/
SCCE drop in hours and live chat: https://science.mcmaster.ca/scce/contact/drop-in-advising.html
Cost of hiring: https://toggl.com/blog/cost-of-hiring-an-employee
Email: soyougotalifescidegree@gmail.com
2021-01-2545 minSo You Got A Lifesci Degree10: Reshaping health technology (with Nisha Almeida)This episode, we chat with Nisha Almeida about her role as a Research Scientist at McGill University's Health Technology Assessment Unit. Nisha tells us about how she helps hospital administration evaluate the value of new health technologies and interventions using the best available scientific evidence. We also talk about conflicting goals between physicians and the importance of end-of-life care.
Health Technology Assessment Unit Website: https://muhc.ca/tau/page/what-is-tau
The Checklist Manifesto: http://atulgawande.com/book/the-checklist-manifesto/
Email: soyougotalifescidegree@gmail.com
Webpage: https...2021-01-1057 minSo You Got A Lifesci Degree9: Biotech Startups (with Gayathri Vijayakumar)This week, we chat with Gayathri Vijayakumar about her work at Scribe Therapeutics, a San Francisco-based biotechnology company. Gayathri explains how she is exploiting viral mechanisms to create targeted CRISPR therapeutics. We also talk about startup culture and the biotech industry as a whole!
Brittany M Art website: www.brittanymart.etsy.com
Brittany M Art Facebook: https://www.facebook.com/
Brittany M Art Instagram: https://www.instagram.com/brittanymart_
Gayathri’s Twitter: https://twitter.com/Gayathri_Vijayk
Hatching Twitter: https://ww...2020-12-281h 07So You Got A Lifesci Degree8: Genetic Counselling (with Jacqueline Leonard)This episode, we chat with Jackie about her role as a genetic counsellor at the Children’s Hospital of Philadelphia! Some of what she says may surprise you - such as how just how much "counselling" can go into the job sometimes. Plus, we talk about her work involving intersex genetic etiologies and differences in sex development.
Brittany M Art website: www.brittanymart.etsy.com
Brittany M Art Facebook: https://www.facebook.com/
Brittany M Art Instagram: https://www.instagram.com/brittanymart
Direct Su...2020-12-141h 16So You Got A Lifesci Degree7: Teaching High School Math (with Talia Asa)Join us this week as we talk to Talia Asa, a math teacher at Abbey Park High School. Talia edumacates us on the different kinds of teachers in Ontario, and how to become one yourself! Plus, philosophical ramblings about the life-long impacts a teacher can have on you.
Brittany M Art website: www.brittanymart.etsy.com
Brittany M Art Facebook: https://www.facebook.com/
Brittany M Art Instagram: https://www.instagram.com/brittanymart_
Not overthinking: www.notoverthinking.com/competitiveness-and-mimetic-traps/
...2020-11-301h 11So You Got A Lifesci Degree6: The Case Against a PhDA SPECIAL episode this week, in which Farida presents the case AGAINST a PhD (for certain situations). Come learn about opportunity costs, the availability of academic positions, and the desirability of PhD holders!
Cal Newport's books: https://www.calnewport.com 80,000 hours site: https://80000hours.org/
Jason Brennan book: https://jhupbooks.press.jhu.edu/title/good-work-if-you-can-get-it.
Email: soyougotalifescidegree@gmail.com
Webpage: https://anchor.fm/soyougotalifescidegree
Patreon: https://www.patreon.com/soyougotalifescidegree?fan_landing=true
Rate us on Apple Podcasts: https...2020-11-1541 minSo You Got A Lifesci Degree5: Pharmaceutical Company Director (with Rizwana Islam)This week we speak to Rizwana Islam, a Director at Takeda, an multinational pharmaceutical company. Rizwana tells us about the types of positions available in the pharmaceutical industry and how to get your foot in the door!
Email: soyougotalifescidegree@gmail.com
Webpage: https://anchor.fm/soyougotalifescidegree
Patreon: https://www.patreon.com/soyougotalifescidegree?fan_landing=true
Rate us on Apple Podcasts: https://podcasts.apple.com/ca/podcast/so-you-got-a-lifesci-degree/id1531348565
Music copyright notice: No Regrets (2015) - Royalty-Free Music by https://audiohub.com2020-11-021h 03So You Got A Lifesci Degree4: Research Proposals Facilitator (with Sibat Anam)This episode, we talk to Sibat Anam, a Research Proposals Facilitator at Ryerson University. This is a great example of a job for lifesci undergrads that neither of us knew existed! Sibat helps faculty members obtain grants, write research proposals, and commercialize their research. We also chat about how he got hired over a crowd of PhD-holders!
Sibat's LinkedIn: https://www.linkedin.com/in/sibatanam/
NSERC: https://www.nserc-crsng.gc.ca/students-etudiants/ug-pc/usra-brpc_eng.asp
Simon Clark video: https://youtu.be/qLLKfmn4gp4
Drawdown book: amazon2020-10-191h 06So You Got A Lifesci Degree3: Medical Illustration and Web Development (with Jessica Zhang)This week’s guest is Jessica Zhang, a freelance medical illustrator and front-end web developer based in Toronto. Jessica currently works at Klick Health, a marketing agency and commercialization partner for life science brands. We talk about what working as a medical illustrator is like, the kinds of positions available in the field, and how she transitioned to web development!
Correction: The Juno coding program runs from 10 AM to 6 PM (not 8AM to 6PM as mentioned in the episode)
Jessica’s front-end web development: Codedbyjessica.com
Je...2020-10-0549 minSo You Got A Lifesci Degree2: Physiotherapy and Clinic Management (with Janna Marvyn)This episode is with Janna Marvyn, a clinic manager and physiotherapist at Pillars of Wellness in Burlington, Ontario. Janna describes what it means to be a clinic manager, and tells us about her work with adults and children undergoing physical rehabilitation for neurological injuries. We also chat about cool new technologies in the field of physio!
Janna’s clinic: http://www.pillarsofwellness.ca
Weekend Wednesday: https://youtu.be/ALaTm6VzTBw
Email: soyougotalifescidegree@gmail.com
Webpage: https://anchor.fm/soyougotalifescidegree
Patreon: https://www.patreon.com/so...2020-09-211h 13So You Got A Lifesci Degree1: Market Access in Pharma (with Kara Griffiths)Our first episode is with Kara Griffiths! Kara is a Senior Manager of Market Access at Gilead Sciences, where she works to get pharmaceuticals covered under insurance policies. We chat about what her role entails, the morality of pharmaceutical companies, and the Master of Biotechnology program at the University of Toronto!
Master of biotechnology program at UofT: https://www.sgs.utoronto.ca/programs/biotechnology/
Email: soyougotalifescidegree@gmail.com
Webpage: https://anchor.fm/soyougotalifescidegree
Patreon: https://www.patreon.com/soyougotalifescidegree?fan_landing=true
...2020-09-0759 minSo You Got A Lifesci DegreeIntroductionWelcome to So You Got A Lifesci Degree, a podcast about the careers you can pursue with an undergrad degree in lifesci! This show is co-hosted by Lisa Shen, a Molecular Biology and Genetic student at McMaster University, and Farida Rahman, a Biology student at McGill University. Each episode, we’ll be interviewing a different guest about their job - interspersed with life shenanigans and squirrel stories! We’re so glad you found us, and hope that you have a wonderful listening journey.
Email: soyougotalifescidegree@gmail.com
Patreon: https://www.patreon.com/soyo...2020-09-0701 min